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METHODS One hundred twenty consecutive potent patients (mean age 40.3 years; range 18-63 years)seeking medical treatment for lifelong PE were enrolled in a prospective phase II study. Moreover,
they were assessed regarding detailed medical and sexual history, intravaginal ejaculatory latency
time (IELT), International Index of Erectile Function (IIEF), and complete physical examina-
tion. The patients received a dapoxetine prescription (30 mg on demand) and unresponded cases
received increased dose (60 mg after 3 months). The patients were evaluated at 1, 3, 6, and 12
months, and requested to complete a multiple-choice global assessment questionnaire regarding
specific reasons for eventual therapy discontinuation.RESULTS Twenty-four of the patients (20%) decided not to start dapoxetine. Fear of using a “drug” was the
most frequently reported reason for treatment nonacceptance (50%) and the cost of treatment
was the reason for 25% of the patients. Ninety-six patients (80%) started the therapy. Twenty-six
percent dropped out after 1 month, 42.7% dropped out after 3 months, 18.7% dropped out at 6
months, 2% dropped out at 12 months, and 10.4% are continuing the therapy after 1 year. The
main reasons were effect below expectations 24.4%, costs 22.1%, side effects 19.8%, loss of
interest in sex 19.8%, and no efficacy 13.9%.CONCLUSION Twenty percent of lifelong PE patients seeking medical treatment for early ejaculation freely
decided not to start treatment with dapoxetine, and roughly 90% of the patients who started
therapy discontinued after 1 year. UROLOGY 82: 620e624, 2013.  2013 Elsevier Inc.remature ejaculation (PE) is a common sexual
dysfunction in men characterized by a short timePto, and a lack of control over, ejaculation and is
associated with distress for patients and their partners.1
Several studies have suggested a dysfunction of the sero-
tonin (5-hydroxytryptamine), dopamine, and epineph-
rine pathways as a biological cause of lifelong PE.2-5
Lifelong PE has been reported as the most common
sexual disease in young men.6 Drug treatment of PE with
an off-label antidepressant selective serotonin reuptake
inhibitor (SSRI) drug, topical anesthetics, and the
narcotic analgesic tramadol were the only therapies until
dapoxetine introduction.7,8 Dapoxetine is the first oral
pharmacological agent indicated for the treatment of menrs declare that they have no relevant financial interests.
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servedaged 18-64 years with premature ejaculation.9 Discon-
tinuation rates for all off-label treatments in patients
seeking medical treatment for lifelong PE were very high.10
Salonia et al10 showed that up to 60% of patients who
received paroxetine, an SSRI drug, for lifelong PE even-
tually discontinued it. The aim of our study was to assess
the acceptance, the discontinuation rate, and reasons for
discontinuation of dapoxetine treatment in patients with
lifelong PE in the setting of real clinical practice.
MATERIAL AND METHODS
A 1-year prospective observational study was conducted in
a single clinical center in which patients affected with PE are
routinely evaluated and treated. Study was conducted according
to the principles outlined in the Declaration of Helsinki. The
local ethics committee approved the study protocol and all
patients signed an informed consent.
Patients
One-hundred twenty consecutive patients affected with and
seeking medical treatment for lifelong PE were enrolled in the
study between July 1, 2009, andOctober 31, 2009. At baseline, all
patients underwent a detailed medical interview comprehensive0090-4295/13/$36.00
http://dx.doi.org/10.1016/j.urology.2013.05.018
Table 1. Baseline characteristics and demographic
statistic for all patients
Number of patients 120
Age y 40.3 (18-63)
Age distribution
18-29 y 18 (15%)
30-39 y 34 (28.3%)
40-49 y 50 (41.6%)
>50 y 18 (15%)
Relationship status
Married 64 (53.3%)
Stable sexual relationship 38 (31.6%)
No stable relationship 18 (15%)
Educational status
Elementary school 0
Secondary school 37 (30.8%)
High school 69 (57.5%)
University degree 14 (11.6%)
Comorbidity 13 (10.8%)of educational status and sexual history, and a complete physical
examination. Patients were also asked to complete an Interna-
tional Index of Erectile Function-Erection Function Domain
(IIEF-EF) questionnaire and subsequently to report their self-
estimated intravaginal ejaculation latency time (IELT) during
a 4-week run-in period during which they were asked to have
sexual intercourse at least 4 times. All patients also underwent the
Meares-Stamey test to exclude infection of the genital tract.
Patients were stratified according to educational status (low
educational level group, including patients with an elementary
and/or secondary school education, and a high educational level
group, including men with a high school and/or university
degree), relationship status (defined as married, stable sexual
relationship if the patients had the same partner for 6 or more
consecutive months, or no stable relationship), and previous
treatment for early ejaculations. IELT was defined as the time
between the start of vaginal intromission and the start of
intravaginal ejaculation.11 According to the new definition of
the International Society of Sexual Medicine,12 lifelong PE was
defined as ejaculation that always or nearly always occurs before
or within about 1 minute of vaginal penetration, the inability to
delay ejaculation on all or nearly all vaginal penetrations, and
negative personal consequences, such as distress, frustration,
and/or avoidance of sexual intimacy.
Inclusion Criteria
For the purposes of this study, the patients were eligible if they
had never undergone dapoxetine treatment, were >18 and <64
years old, had a negative neurological physical examination,
were not suffering from any sexual disorders other than lifelong
PE or any Diagnostic and Statistical Manual of Mental Disorders
IV axis I disorder, had a negative Meares-Stamey test (thus
excluding infection of the genital tract), did not complain of
any organic cause of PE, including anatomic abnormalities, had
a normal IIEF-erectile function domain score at baseline (IIEF-
EF 26),13 were in a heterosexual relationship with a sexually
active partner, did not have a history or were not currently
abusing alcohol or using illicit drugs, or did not have an organic
illness causing limitations in assuming SSRIs. Patients were not
reimbursed for participation in this observational survey. No
other PE therapies were offered during the study period.
Study Protocol
After the 4-week run-in period, patients received dapoxetine
(taken 1-3 hours before the planned intercourse) 30 mg on
demand. A titration-dose to 60 mg was consented after 3 months
in case of low efficacy. Thereafter, the patients could stay with
the same on-demand treatment for the next month, or dis-
continue. Patients were re-evaluated at 1, 3, 6, and 12 months,
repeating IELT measurement and, in case of treatment discon-
tinuation, answering multiple-choice global assessment questions
regarding specific reasons for eventual therapy discontinuation.
Main Outcome Measures
The primary end points were acceptance and discontinuation
rates for dapoxetine treatment in patients seeking medical
treatment for lifelong PE. Other variables evaluated were the
reasons for nonacceptance of treatment or discontinuation.
Statistical Analyses
The present study was designed as a prospective cohort study.
Patients who assumed at least a single dose of dapoxetine wereUROLOGY 82 (3), 2013included in the intention-to-treat population and analyzed. A
comparison was made between baseline characteristics of
patients continuing or discontinuing the treatment using the
t test and Wilcoxon Mann-Whitney test for continuous vari-
ables, and the chi-square test for categorical variables. Analysis
of variance (ANOVA) was used for comparing IIEF-EF and
IELT mean scores. Bonferroni adjustment test was also used at
the second stage of the ANOVA. The effect size between the
means (Cohen’s d) was also calculated. Moreover, the difference
between the group of patients who had discontinued or not
accepted the therapy and the other group were compared by
using ANOVA test, the Fischer exact test, or chi-square test
when appropriate. The ANOVA test was also used for univar-
iate analysis and the log-rank test (Mantel Cox) for multivariate
analysis. The parameters considered for univariate and multi-
variate analysis are as follows: age, education level, smoking
habits, and body mass index.
Statistical significance was achieved when P was <.05. All
reported P values were 2-sided. Statistics were prepared by
a qualified technician by using SPSS 11.5 for Apple-Macintosh
(SPSS, Inc., Chicago, IL).RESULTS
Table 1 lists the baseline characteristics and demographic
statistics for all patients. Overall, men suffering from
lifelong PE reported general good health, with a low
proportion of patients detailing a significant medical
comorbidity (10.8%); among those men, 3 patients
suffered from type 2 diabetes mellitus, 1 reported an old
myocardial infarction, 3 had benign prostatic hyperplasia,
5 had hypertension, and 1 had atopic asthma. Mean re-
ported IELT was 0.9 minutes (range 0.5-1 minute). All
patients reported full sexual potency with a mean IIEF-EF
of 27. Twenty-four patients (20%) decided not to start
dapoxetine. Fear of using a “drug” (12 of 24 patients;
50%) was the main reason for treatment nonacceptance;
the cost was the reason for 6 patients (25%). Ninety-six
patients (80%) started therapy. Twenty-five patients
(26%) dropped out at 1 month; the main reasons were
side effects for 13 patients (52%) and no efficacy for 12621
Figure 1. Number of patients seeking medical treatment for premature ejaculation (PE; V0), start and discontinuation rate
from dapoxetine treatment at 1 (V1), 3 (V2), 6 (V3), and 12 months (V4). (Color version available online.)
Figure 2. Reasons for treatment nonacceptance and discontinuation. (Color version available online.)(48%). Forty-one patients (42.7%) dropped out at 3
months because of treatment effect below expectations
for 21 patients (51.2%), temporary loss of interest in sex
because of relationship issues for 6 (14.6%), costs for 10
(24.3%), and side effects for 4 (9.7%). Eighteen of 75
patients dropped out at 6 months; the main reason was
loss of interest for 9 patients (50%), and costs for 9
(50%). Two patients (2.08%) dropped out at 12 months
(Figs. 1 and 2). All the patients who dropped out (74 of
84 patients) reported that latency time decreased to
pretreatment levels after discontinuation. Only 9 of 74
patients (12.1%) resorted to other therapies: 5 used
topical anesthetic agents; 3 others used SSRIs, and 1 used
psychotherapy. Ten patients (10.4%) were continuing
the therapy after 1 year at the dosage of 30 mg in 8 cases622and 60 mg in 2 cases, and assumed a mean of 2 pills per
month. No statistically significant differences in age,
educational status, or comorbidity were observed between
patients who continued the treatment and patients who
dropped out. Eighteen patients had the highest dosage
and, among them, only 2 were still on treatment at 12
months. Overall, the 1, 3, 6, and 12-month estimated
IELT was, respectively, 3.1 minutes (range 1-5 minutes),
3.2 minutes (range 1-5 minutes), 3.8 minutes (range 2.5-5
minutes), and 3.6 minutes (2.5-5 minutes). Patients were
also divided in subgroups according to their reason for
discontinuation in order to compare their IELT at month
1 (Fig. 3). Interestingly, IELT was significantly and sim-
ilarly improved compared to baseline in patients who
continued the treatment and in all subgroups thatUROLOGY 82 (3), 2013
96 PATIENTS
12 NO EFFICACY
84
21 EFFECTS BELOW
 EXPECTATIONS 19 COSTS 17 SIDE EFFECTS
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Figure 3. Intravaginal ejaculatory latency time (IELT) pretreatment and post-treatment with dapoxetine in all 84 patients
(range 1.3-3.1 minutes); in 10 patients still receiving therapy after 1 year (range 1.29-3.33 minutes); 21 patients had effects
below expectation (range, 1.4-2.85 minutes); 19 patients dropped out because of the cost (range 1.31-3 minutes); 17
patients had side effects (range 1.29-2.94 minutes); and 17 patients had loss of interest in sex (range 1.3-3.3 minutes).
(Color version available online.)discontinued for any cause. The most common side effects
included nausea, dizziness, and headache. No severe side
effects, such as self-harm, aggressive behavior, serotonin
syndrome, postural hypotension, or syncope occurred.DISCUSSION
Discontinuation rates for SSRI administered as “off-label”
treatment for lifelong PE is very high in most published
series.10 The main problem is the high rate of nonac-
ceptance of treatments; in fact, although PE is a common
sexual disorder among adult men, only 9% of affected
patients reported having consulted a physician for the
condition, and 91.5% reported little or no improvement
as a result of seeking treatment.14 A very important
reason for not starting therapy was the patient’s fear of
using an “antidepressant drug” with no on-label indica-
tion for treating PE, as reported from Salonia et al10
regarding paroxetine: 30.1% of patients with lifelong PE
decided not to begin treatment and 30.8% of those who
freely decided to start paroxetine therapy discontinued it
during the subsequent 3 months.10 To our knowledge, no
precise data is available in the literature about long-term
acceptance/discontinuation rates for other treatments forUROLOGY 82 (3), 2013premature ejaculation. A very high discontinuation rate is
generally reported for psychological and behavioral
therapy (eg, the “stop-start” strategy [stopping coitus in
situ and restarting after a delay] and its evolution to
the “squeeze” technique [the physical application of
pressure at the base of the head of the penis]),15,16 despite
promising short-term results, topical anesthetic agents
(lidocaine-prilocaine and severance-secret [SS] cream)
are the oldest pharmacological therapies, but no long-
term treatment rates are reported.17
Introduction in the market of dapoxetine, the first oral
pharmacological agent indicated for the treatment of men
with PE, was accompanied with great expectation because
of the optimal efficacy/safety profile exhibited in the
phase 3 registrative trials and the novelty of a drug
specifically designed and labeled for PE.18
However, clinical practice experience with dapoxetine
hereby reported, albeit confirming efficacy in increasing
baseline IELT in patients with PE also reveals that most
factors for the high dropout rate for SSRI had not been
overcome by this new formulation.
Acceptance for the treatment remains a problem:
about 1 of 5 patients (20%) refused to assume a drug to
treat his PE, even if perfectly on-label. These data623
confirm how a wrong cultural approach to PE may be
a determinant, as they prevent patients from consider-
ing PE a “disease” and, thus, from accepting any phar-
macological treatment. Reluctance of men with PE to
consider themselves as “patient” candidates to a pharma-
cological treatment may also arise from their otherwise
healthy status. In fact, in the present series of men with
lifelong PE, a significant organic comorbidity was re-
ported in only 10.8% of cases, with most patients being
totally naive of any pharmacological treatment.
Efficacy and safety are not fully satisfactory: of 96
patients that started the treatment, 86 discontinued it: 33
(38.3%) abandoned the drug because of lack of efficacy or
efficacy below expectation and 17 (19.8%) because of
side effects. Overall, an unfavorable cost/benefit ratio was
reported by 22.1% of patients and resulted in the most
relevant cause of dropouts in our series, thus raising more
than a question about dapoxetine’s handiness. It is worth
noting that efficacy, as measured by IELT, at 1 month was
similar between patients who eventually dropout and
those remaining in treatment for the whole 12-month
study period. This observation reveals how a two-time
or three-time increase of IELT can be either satisfying
or totally disappointing for different patients whose
expectancies from treatment are probably affected by
a different “idea” of how long normal intercourse should
last. A further issue may have been the dosing protocol
“on demand.” Although dapoxetine on demand has never
been compared to a daily SSRI assumption in terms of
patents preference and satisfaction, Salonia et al. showed
that in PE patients daily treatment with paroxetine was
better accepted than paroxetine “as needed.”10 Daily
dosing of the 5-phosphodiesterase inhibitor tadalafil is
suggested as a treatment for erectile dysfunction in
couples who prefer spontaneous rather than scheduled
sexual activities.19 Similarly, it may be argued that on-
demand assumption of the short-acting dapoxetine
might be seen in the couple as a factor negatively
affecting sexual naturalness.
Finally, costs and relationship problems together
account for 41.9% of dropout, reinforcing the importance
of cultural, personal, and socioeconomic context in
affecting the adherence to treatment for PE. Unfortu-
nately, none of the patients in our series received
psychosexual counseling during the 12-month follow-up
period and this may have affected the dropout rate.
CONCLUSIONS
In our clinical practice-based series, dapoxetine produced
a significant improvement of IELT, consistent with data
reported in registrative trials. However, only 1 of 10
patients continued to assume the treatment after 12
months. Main reasons for treatment discontinuation were624efficacy below expectations, side effects, and costs.
Premature ejaculation confirms to be a very challenging
condition in which clinical trial results are hardly trans-
ferable to the clinical practice.
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